Literature DB >> 23345063

Immune responses elicited by apoB-100-derived peptides in mice.

Chrysoulla Pierides1, Alexandra Bermudez-Fajardo, Gunilla Nordin Fredrikson, Jan Nilsson, Ernesto Oviedo-Orta.   

Abstract

Peptides derived from apolipoprotein B (apoB)-100 have been previously used in vaccine preparations to treat atherosclerosis. Such vaccines have been shown to reduce atherosclerotic plaque development by 50 % in experimental animals, and this effect is associated with induction of T helper (Th)2 immune responses. In this study we immunised apolipoprotein E-deficient (apoE(-/-)) mice with apoB-100-derived peptides P2, P45 and P210. Animals received BSA-conjugated peptides or peptide-loaded bone marrow-derived dendritic cells (DCs). We used enzyme-linked immunosorbent assays to assess the synthesis of anti-peptide-specific IgG1 and IgG2a as well as the levels of interleukin (IL-)10 and interferon gamma (IFN-γ) in plasma of immunised animals. We also measured the effect of immunisation on the number of spleen-derived CD4(+) and CD8(+) regulatory T cells (Tregs) in these animals. Peptide and peptide-loaded DC immunisation significantly increased the levels of peptide-specific immunoglobulins and the number of Tregs in apoE(-/-) mice. This was accompanied by a significant increase in the secretion of IL-10 with no effect on IFN-γ levels. The results also show that the peptides can modulate the homing properties of DCs. Altogether, this study provides novel evidence for the immune mechanisms excerpted by apoB-100-derived peptides and their effect on Tregs and DCs relevant to their use in vaccine preparations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345063     DOI: 10.1007/s12026-013-8383-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  31 in total

1.  Expressing and purifying an anti-atherosclerosis polypeptide vaccine in Escherichia coli.

Authors:  Qi Gaofu; Wu Jie; Yang Xin; Rouel S Roque; Liu Jingjing
Journal:  Protein Expr Purif       Date:  2004-08       Impact factor: 1.650

Review 2.  2. Dendritic cells as regulators of immunity and tolerance.

Authors:  Natalija Novak; Thomas Bieber
Journal:  J Allergy Clin Immunol       Date:  2008-02       Impact factor: 10.793

3.  Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms.

Authors:  Elizabeth A Wohlfert; Frank C Nichols; Erin Nevius; Robert B Clark
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

4.  Use of glutaraldehyde as a coupling agent for proteins and peptides.

Authors:  M Reichlin
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

5.  The use of carbodiimides in the preparation of immunizing conjugates.

Authors:  S Bauminger; M Wilchek
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.

Authors:  Gunilla Nordin Fredrikson; Ingrid Söderberg; Marie Lindholm; Paul Dimayuga; Kuang-Yuh Chyu; Prediman K Shah; Jan Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-20       Impact factor: 8.311

7.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

8.  Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients.

Authors:  Jeroen N Stoop; Mark A A Claassen; Andrea M Woltman; Rekha S Binda; Ernst J Kuipers; Harry L A Janssen; Renate G van der Molen; Andre Boonstra
Journal:  Clin Immunol       Date:  2008-09-26       Impact factor: 3.969

9.  Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice.

Authors:  Christophe Combadière; Stéphane Potteaux; Mathieu Rodero; Tabassome Simon; Adeline Pezard; Bruno Esposito; Régine Merval; Amanda Proudfoot; Alain Tedgui; Ziad Mallat
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

10.  Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions.

Authors:  Isabel Gonçalves; Mihaela Nitulescu; Mikko P S Ares; Gunilla Nordin Fredrikson; Bo Jansson; Zhan-Chun Li; Jan Nilsson
Journal:  Atherosclerosis       Date:  2008-11-30       Impact factor: 5.162

View more
  13 in total

Review 1.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 2.  Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

Authors:  Peter Libby; Andrew H Lichtman; Göran K Hansson
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

Review 3.  Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.

Authors:  Charlotte Spitz; Holger Winkels; Christina Bürger; Christian Weber; Esther Lutgens; Göran K Hansson; Norbert Gerdes
Journal:  Cell Mol Life Sci       Date:  2015-10-30       Impact factor: 9.261

Review 4.  Vaccination to modulate atherosclerosis.

Authors:  Takayuki Kimura; Kevin Tse; Alessandro Sette; Klaus Ley
Journal:  Autoimmunity       Date:  2015-02-16       Impact factor: 2.815

Review 5.  The role of T and B cells in human atherosclerosis and atherothrombosis.

Authors:  E Ammirati; F Moroni; M Magnoni; P G Camici
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

6.  Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis.

Authors:  Xianwen Yi; Ying Wang; Zhenquan Jia; Sylvia Hiller; Jun Nakamura; J Christopher Luft; Shaomin Tian; Joseph M DeSimone
Journal:  J Biomed Nanotechnol       Date:  2020-04-01       Impact factor: 4.099

7.  Chlamydomonas reinhardtii chloroplasts express an orally immunogenic protein targeting the p210 epitope implicated in atherosclerosis immunotherapies.

Authors:  Josué I Beltrán-López; Andrea Romero-Maldonado; Elizabeth Monreal-Escalante; Bernardo Bañuelos-Hernández; Luz Mt Paz-Maldonado; Sergio Rosales-Mendoza
Journal:  Plant Cell Rep       Date:  2016-02-17       Impact factor: 4.570

8.  Assessment of Carrot Callus as Biofactories of an Atherosclerosis Oral Vaccine Prototype.

Authors:  Dania O Govea-Alonso; Marlene A Tello-Olea; Josué Beltrán-López; Elizabeth Monreal-Escalante; Jorge A Salazar-Gonzalez; Bernardo Bañuelos-Hernández; Sergio Rosales-Mendoza
Journal:  Mol Biotechnol       Date:  2017-12       Impact factor: 2.695

9.  Immunization using ApoB-100 peptide-linked nanoparticles reduces atherosclerosis.

Authors:  Kuang-Yuh Chyu; Xiaoning Zhao; Jianchang Zhou; Paul C Dimayuga; Nicole Wm Lio; Bojan Cercek; Noah T Trac; Eun Ji Chung; Prediman K Shah
Journal:  JCI Insight       Date:  2022-06-08

10.  Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100.

Authors:  Kevin Tse; Ayelet Gonen; John Sidney; Hui Ouyang; Joseph L Witztum; Alessandro Sette; Harley Tse; Klaus Ley
Journal:  Front Immunol       Date:  2013-12-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.